

July 12, 2018

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Notification**


Dear Sir / Madam,

We hereby inform that the manufacturing facility of Zydus Hopsira Oncology Private Limited, a 50:50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is "closed" and states that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from 5th to 12th April, 2018.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

for, 
UPEN H. SHAH
COMPANY SECRETARY



Zydus Hospira JV receives EIR Report for its Manufacturing Facility at Ahmedabad

Ahmedabad, India, July 12, 2018

Zydus Hospira Oncology Pvt. Ltd., a 50: 50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is “closed” and states that the inspection classification of this facility is ‘Voluntary Action Indicated’ (VAI). The manufacturing plant had completed the USFDA audit from 5th to 12th April 2018.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 22000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
